{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:50:09Z","timestamp":1791607809437,"version":"4.3.4"},"reference-count":46,"publisher":"Japan Academy","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Proc. Jpn. Acad., Ser. B","Proceedings of the Japan Academy. Ser. B: Physical and Biological Sciences"],"published-print":{"date-parts":[[2026,10,9]]},"DOI":"10.2183\/pjab.102.022","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:35Z","timestamp":1791497615000},"page":"303-313","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in systemic therapy for biliary tract cancer: Evidence from Japan and recommendations in guidelines"],"prefix":"10.2183","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"OKUSAKA","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-6117","authenticated-orcid":false,"given":"Junji","family":"FURUSE","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"KONISHI","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5091-1078","authenticated-orcid":false,"given":"Masayuki","family":"OHTSUKA","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Graduate School of Medicine, Chiba University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"993","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1) Banales, J.M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J.B., Invernizzi, P. et al. (2016) Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. <b>13<\/b>, 261\u2013280. doi: 10.1038\/nrgastro.2016.51.","DOI":"10.1038\/nrgastro.2016.51"},{"key":"2","unstructured":"2) The Japanese Society of Hepato-Biliary-Pancreatic Surgery (2025) Clinical Practice Guidelines for the Management of Biliary Tract Cancers: The 4th edition. Igakutosho Shuppan Co. Ltd., Tokyo."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Ducreux, M., Rougier, P., Fandi, A., Clavero-Fabri, M.C., Villing, A.L., Fassone, F. et al. (1998) Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann. Oncol. <b>9<\/b>, 653\u2013656. doi: 10.1023\/a:1008241008379.","DOI":"10.1023\/A:1008241008379"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4) Harvey, J.H., Smith, F.P. and Schein, P.S. (1984) 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J. Clin. Oncol. <b>2<\/b>, 1245\u20131248. doi: 10.1200\/JCO.1984.2.11.1245.","DOI":"10.1200\/JCO.1984.2.11.1245"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Patt, Y.Z., Jones, D.V. Jr., Hoque, A., Lozano, R., Markowitz, A., Raijman, I. et al. (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J. Clin. Oncol. <b>14<\/b>, 2311\u20132315. doi: 10.1200\/JCO.1996.14.8.2311.","DOI":"10.1200\/JCO.1996.14.8.2311"},{"key":"6","unstructured":"6) Patt, Y.Z., Hassan, M.M., Lozano, R.D., Waugh, K.A., Hoque, A.M., Frome, A.I. et al. (2001) Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin. Cancer Res. <b>7<\/b>, 3375\u20133380."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Valle, J.W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R. et al. (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 The UK ABC-01 Study. Br. J. Cancer <b>101<\/b>, 621\u2013627. doi: 10.1038\/sj.bjc.6605211.","DOI":"10.1038\/sj.bjc.6605211"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Valle, J., Wasan, H., Palmer, D.H., Cunningham, D., Anthoney, A., Maraveyas, A. et al. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. <b>362<\/b>, 1273\u20131281. doi: 10.1056\/NEJMoa0908721.","DOI":"10.1056\/NEJMoa0908721"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A. et al. (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer <b>103<\/b>, 469\u2013474. doi: 10.1038\/sj.bjc.6605779.","DOI":"10.1038\/sj.bjc.6605779"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Khan, S.A., Davidson, B.R., Goldin, R.D., Heaton, N., Karani, J., Pereira, S.P. et al. (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut <b>61<\/b>, 1657\u20131669. doi: 10.1136\/gutjnl-2011-301748.","DOI":"10.1136\/gutjnl-2011-301748"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Benavides, M., Anton, A., Gallego, J., Gomez, M.A., Jimenez-Gordo, A., La Casta, A. et al. (2015) Biliary tract cancers: SEOM clinical guidelines. Clin. Transl. Oncol. <b>17<\/b>, 982\u2013987. doi: 10.1007\/s12094-015-1436-2.","DOI":"10.1007\/s12094-015-1436-2"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12) Benson, A.B., D\u2019Angelica, M.I., Abrams, T., Abbott, D.E., Ahmed, A., Anaya, D.A. et al. (2023) NCCN Guidelines(R) Insights: Biliary Tract Cancers, Version 2.2023. J. Natl. Compr. Canc. Netw. <b>21<\/b>, 694\u2013704. doi: 10.6004\/jnccn.2023.0035.","DOI":"10.6004\/jnccn.2023.0035"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13) Miyazaki, M., Yoshitomi, H., Miyakawa, S., Uesaka, K., Unno, M., Endo, I. et al. (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J. Hepatobiliary Pancreat. Sci. <b>22<\/b>, 249\u2013273. doi: 10.1002\/jhbp.233.","DOI":"10.1002\/jhbp.233"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Morizane, C., Okusaka, T., Mizusawa, J., Katayama, H., Ueno, M., Ikeda, M. et al. (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. <b>30<\/b>, 1950\u20131958. doi: 10.1093\/annonc\/mdz402.","DOI":"10.1093\/annonc\/mdz402"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Ioka, T., Kanai, M., Kobayashi, S., Sakai, D., Eguchi, H., Baba, H. et al. (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J. Hepatobiliary Pancreat. Sci. <b>30<\/b>, 102\u2013110. doi: 10.1002\/jhbp.1219.","DOI":"10.1002\/jhbp.1219"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Oh, D.Y., Ruth He, A., Qin, S., Chen, L.T., Okusaka, T., Vogel, A. et al. (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. <b>1<\/b>, EVIDoa2200015. doi: 10.1056\/EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Kelley, R.K., Ueno, M., Yoo, C., Finn, R.S., Furuse, J., Ren, Z. et al. (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet <b>401<\/b>, 1853\u20131865. doi: 10.1016\/S0140-6736(23)00727-4.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Lamarca, A., Palmer, D.H., Wasan, H.S., Ross, P.J., Ma, Y.T., Arora, A. et al. (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. <b>22<\/b>, 690\u2013701. doi: 10.1016\/S1470-2045(21)00027-9.","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19) Sasaki, T., Isayama, H., Nakai, Y., Mizuno, S., Yamamoto, K., Yagioka, H. et al. (2012) Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest. New Drugs <b>30<\/b>, 708\u2013713. doi: 10.1007\/s10637-010-9553-9.","DOI":"10.1007\/s10637-010-9553-9"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Sasaki, T., Isayama, H., Yashima, Y., Yagioka, H., Kogure, H., Arizumi, T. et al. (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology <b>77<\/b>, 71\u201374. doi: 10.1159\/000226214.","DOI":"10.1159\/000226214"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21) Suzuki, E., Ikeda, M., Okusaka, T., Nakamori, S., Ohkawa, S., Nagakawa, T. et al. (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother. Pharmacol. <b>71<\/b>, 1141\u20131146. doi: 10.1007\/s00280-013-2106-0.","DOI":"10.1007\/s00280-013-2106-0"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Abou-Alfa, G.K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R. et al. (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. <b>21<\/b>, 671\u2013684. doi: 10.1016\/S1470-2045(20)30109-1.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23) Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J.W., Morizane, C., Karasic, T.B. et al. (2023) Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. N. Engl. J. Med. <b>388<\/b>, 228\u2013239. doi: 10.1056\/NEJMoa2206834.","DOI":"10.1056\/NEJMoa2206834"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Shen, L., Duan, H., Kuwahara, T., Satoh, T., Ma, X., Yan, S. et al. (2025) Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions\/rearrangements: a multicenter, open-label, Phase 2 study. Jpn. J. Clin. Oncol. <b>55<\/b>, 1229\u20131236. doi: 10.1093\/jjco\/hyaf119.","DOI":"10.1093\/jjco\/hyaf119"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25) Abou-Alfa, G.K., Macarulla, T., Javle, M.M., Kelley, R.K., Lubner, S.J., Adeva, J. et al. (2020) Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. <b>21<\/b>, 796\u2013807. doi: 10.1016\/S1470-2045(20)30157-1.","DOI":"10.1016\/S1470-2045(20)30157-1"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26) Javle, M., Borad, M.J., Azad, N.S., Kurzrock, R., Abou-Alfa, G.K., George, B. et al. (2021) Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. <b>22<\/b>, 1290\u20131300. doi: 10.1016\/S1470-2045(21)00336-3.","DOI":"10.1016\/S1470-2045(21)00336-3"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.Y., Banerjee, S., Gonzalez-Martin, A. et al. (2024) Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. <b>42<\/b>, 47\u201358. doi: 10.1200\/JCO.23.02005.","DOI":"10.1200\/JCO.23.02005"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28) Ohba, A., Morizane, C., Kawamoto, Y., Komatsu, Y., Ueno, M., Kobayashi, S. et al. (2024) Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): A multicenter, single-arm, phase II trial. J. Clin. Oncol. <b>42<\/b>, 3207\u20133217. doi: 10.1200\/JCO.23.02010.","DOI":"10.1200\/JCO.23.02010"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29) Harding, J.J., Fan, J., Oh, D.Y., Choi, H.J., Kim, J.W., Chang, H.M. et al. (2023) Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. <b>24<\/b>, 772\u2013782. doi: 10.1016\/S1470-2045(23)00242-5.","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30) Nakamura, Y., Mizuno, N., Sunakawa, Y., Canon, J.L., Galsky, M.D., Hamilton, E. et al. (2023) Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): A phase II basket study. J. Clin. Oncol. <b>41<\/b>, 5569\u20135578. doi: 10.1200\/JCO.23.00606.","DOI":"10.1200\/JCO.23.00606"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31) Marabelle, A., Le, D.T., Ascierto, P.A., Di Giacomo, A.M., De Jesus-Acosta, A., Delord, J.P. et al. (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. <b>38<\/b>, 1\u201310. doi: 10.1200\/JCO.19.02105.","DOI":"10.1200\/JCO.19.02105"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32) Marabelle, A., O\u2019Malley, D.M., Hendifar, A.E., Ascierto, P.A., Motola-Kuba, D., Penel, N. et al. (2025) Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nat. Cancer <b>6<\/b>, 253\u2013258. doi: 10.1038\/s43018-024-00894-y.","DOI":"10.1038\/s43018-024-00894-y"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33) Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K. et al. (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. <b>21<\/b>, 1353\u20131365. doi: 10.1016\/S1470-2045(20)30445-9.","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34) Subbiah, V., Lassen, U., Elez, E., Italiano, A., Curigliano, G., Javle, M. et al. (2020) Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. <b>21<\/b>, 1234\u20131243. doi: 10.1016\/S1470-2045(20)30321-1.","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35) Hong, D.S., DuBois, S.G., Kummar, S., Farago, A.F., Albert, C.M., Rohrberg, K.S. et al. (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. <b>21<\/b>, 531\u2013540. doi: 10.1016\/S1470-2045(19)30856-3.","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36) Doebele, R.C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A.T., Farago, A.F. et al. (2020) Entrectinib in patients with advanced or metastatic fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. <b>21<\/b>, 271\u2013282. doi: 10.1016\/S1470-2045(19)30691-6.","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37) Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J. et al. (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. <b>23<\/b>, 1261\u20131273. doi: 10.1016\/S1470-2045(22)00541-1.","DOI":"10.1016\/S1470-2045(22)00541-1"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38) Subbiah, V., Cassier, P.A., Siena, S., Garralda, E., Paz-Ares, L., Garrido, P. et al. (2022) Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial. Nat. Med. <b>28<\/b>, 1640\u20131645. doi: 10.1038\/s41591-022-01931-y.","DOI":"10.1038\/s41591-022-01931-y"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39) Primrose, J.N., Fox, R.P., Palmer, D.H., Malik, H.Z., Prasad, R., Mirza, D. et al. (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. <b>20<\/b>, 663\u2013673. doi: 10.1016\/S1470-2045(18)30915-X.","DOI":"10.1016\/S1470-2045(18)30915-X"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40) Nakachi, K., Ikeda, M., Konishi, M., Nomura, S., Katayama, H., Kataoka, T. et al. (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet <b>401<\/b>, 195\u2013203. doi: 10.1016\/S0140-6736(22)02038-4.","DOI":"10.1016\/S0140-6736(22)02038-4"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41) Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M. et al. (2018) Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br. J. Surg. <b>105<\/b>, 192\u2013202. doi: 10.1002\/bjs.10776.","DOI":"10.1002\/bjs.10776"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42) Edeline, J., Benabdelghani, M., Bertaut, A., Watelet, J., Hammel, P., Joly, J.P. et al. (2019) Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A randomized phase III study. J. Clin. Oncol. <b>37<\/b>, 658\u2013667. doi: 10.1200\/JCO.18.00050.","DOI":"10.1200\/JCO.18.00050"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Goetze, T.O., Vogel, A., Pratschke, J., Behrend, M., Reim, D., Schnitzbauer, A.A. et al. (2025) Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed adjuvant therapy in biliary tract cancer: Final results from the phase III AIO\/CALGP\/ACO-GAIN-Trial. J. Clin. Oncol. <b>43<\/b>, 4008. doi: 10.1200\/JCO.2025.43.16_suppl.40.","DOI":"10.1200\/JCO.2025.43.16_suppl.4008"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Engineer, R., Goel, M., Ostwal, V., Patkar, S., Gudi, S., Ramaswamy, A. et al. (2025) A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB). J. Clin. Oncol. <b>43<\/b>, 4007. doi: 10.1200\/JCO.2025.43.16_suppl.400.","DOI":"10.1200\/JCO.2025.43.16_suppl.4007"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45) Nara, S., Ioka, T., Ogawa, G., Kataoka, T., Sano, Y., Esaki, M. et al. (2023) Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT). J. Clin. Oncol. <b>41<\/b>, TPS621. doi: 10.1200\/JCO.2023.41.4_suppl.TPS621.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS621"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46) Shi, G.M., Huang, X.Y., Liang, F., Liang, X., Dong, R., Ye, Q.H. et al. (2026) Neoadjuvant GOLP in resectable high-risk intrahepatic cholangiocarcinoma. N. Engl. J. Med. <b>394<\/b>, 983\u2013995. doi: 10.1056\/NEJMoa2513918.","DOI":"10.1056\/NEJMoa2513918"}],"container-title":["Proceedings of the Japan Academy, Series B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/102\/8\/102_pjab.102.022\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:38:31Z","timestamp":1791607111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/pjab\/102\/8\/102_pjab.102.022\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2183\/pjab.102.022","relation":{},"ISSN":["0386-2208","1349-2896"],"issn-type":[{"value":"0386-2208","type":"print"},{"value":"1349-2896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"pjab.102.022"}}